In the Journals

Aflibercept reduces subfoveal fluid in eyes with persistent exudative AMD

Aflibercept yielded positive anatomic results in cases of exudative age-related macular degeneration that were resistant to ranibizumab or bevacizumab, according to a study.

“Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab,” the study authors said.

The retrospective study included 353 eyes with exudative AMD and persistent fluid identified on spectral-domain optical coherence tomography (SD-OCT) despite regular treatment with ranibizumab 0.5 mg and/or bevacizumab 1.25 mg. Eyes received an average of 20 injections of ranibizumab or bevacizumab.

Treatment was switched to intravitreal aflibercept 2 mg (Eylea, Regeneron). Mean patient age at the time of the switch was 81 years.

After the switch, eyes were re-evaluated for a mean of 32 days. Aflibercept administration was monthly but treatment was extended to 6 to 8 weeks for 21 patients.

Twenty-eight eyes of 28 patients had persistent fluid after an average of 20 ranibizumab or bevacizumab injections. Anatomic improvement was seen in 25 of these 28 eyes at 1 month (89%); five eyes (18%) were dry after one aflibercept injection.

Central subfoveal thickness improved from 295 μm to 272 μm after one aflibercept injection; the improvement was statistically significant (P < .001).

No adverse events were reported, the authors said.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.

Aflibercept yielded positive anatomic results in cases of exudative age-related macular degeneration that were resistant to ranibizumab or bevacizumab, according to a study.

“Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab,” the study authors said.

The retrospective study included 353 eyes with exudative AMD and persistent fluid identified on spectral-domain optical coherence tomography (SD-OCT) despite regular treatment with ranibizumab 0.5 mg and/or bevacizumab 1.25 mg. Eyes received an average of 20 injections of ranibizumab or bevacizumab.

Treatment was switched to intravitreal aflibercept 2 mg (Eylea, Regeneron). Mean patient age at the time of the switch was 81 years.

After the switch, eyes were re-evaluated for a mean of 32 days. Aflibercept administration was monthly but treatment was extended to 6 to 8 weeks for 21 patients.

Twenty-eight eyes of 28 patients had persistent fluid after an average of 20 ranibizumab or bevacizumab injections. Anatomic improvement was seen in 25 of these 28 eyes at 1 month (89%); five eyes (18%) were dry after one aflibercept injection.

Central subfoveal thickness improved from 295 μm to 272 μm after one aflibercept injection; the improvement was statistically significant (P < .001).

No adverse events were reported, the authors said.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.